Clinical Trials for Chaperone Drug to be resumed

Category: Archive
March 7, 2011

Amicus Therapeutics Announces FDA Agreement to Commence Phase 2 Study of AT2220 Co-administered with Enzyme Replacement Therapy for Pompe Disease

Amicus issued a new press release today announcing new clinical trials with their Chaperone drug: “Amicus Therapeutics… today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220… Based on data provided by Amicus, the FDA agreed with the Company’s proposal to resume clinical development of AT2220, starting with a new Phase 2 study designed to evaluate the use of AT2220 when co-administered with enzyme replacement therapy (ERT) in subjects with Pompe disease. The Company expects to commence this study in the first half of 2011 and to report preliminary results in the second half of 2011…”

Read the complete Amicus press release.

Back to news articles